# A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics

> **NCT01833923** · PHASE1 · COMPLETED · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 35 (actual)

## Conditions studied

- Advanced Cancer

## Interventions

- **DRUG:** anlotinib

## Key facts

- **NCT ID:** NCT01833923
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2015-10
- **Final completion:** 2015-10
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2015-10-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01833923

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01833923, "A Phase I Study of Anlotinib on Tolerance and Pharmacokinetics". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01833923. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*